Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy. (PubMed, Front Pharmacol) - Nov 28, 2024 - "Elevated CISD2 levels were found to be associated with decreased sensitivity of DLBCL patients to the R-CHOP regimen, as indicated by bioinformatics and clinical cohort analysis...Treatment of DLBCL cell lines with Erastin led to decreased CISD2 levels...Our findings suggest that CISD2 may play a role in the drug resistance observed in DLBCL patients. Inhibition of CISD2 could enhance ferroptosis and ferritinophagy, potentially improving the sensitivity of DLBCL cells to DOX treatment."
Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • BECN1 • FTH1 • GPX4 • NCOA4
|
|
Chaofeng Zhang; Qi Lin; Siting Zhan; Xiongpeng Zhu; Yanjun He; Zhiqun Pan; Zhongyi You
|